Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Morgan Stanley 16th Annual
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on September 4, 2018 , the Compensation Committee of
View HTML
Toggle Summary Sage Therapeutics Announces The Lancet Publishes Integrated Data from Pivotal Trials for Brexanolone Injection in Postpartum Depression
Results from pivotal trials consistently showed treatment with brexanolone injection provided significant and rapid reduction in depressive symptoms within days of initiating therapy Treatment response was durable over the follow-up period, across three placebo-controlled trials ZULRESSO™
View HTML
Toggle Summary Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
Conditional acceptance granted by U.S. Food and Drug Administration ( FDA ) for the proprietary name ZULRESSO™ for Sage’s intravenous formulation of brexanolone Continuing to execute commercial build and launch readiness for ZULRESSO™ (brexanolone injection) in postpartum depression ahead of PDUFA
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on August 1, 2018 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics to Present at Canaccord 38th Annual Growth Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Canaccord 38th Annual
View HTML
Toggle Summary Sage Therapeutics to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 24, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 5, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 2, 2018 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea
Collaboration intended to accelerate development of SAGE-217 in key Asian markets and supports Sage’s mission to bring transformational medicines to patients around the world Collaboration supports Shionogi’s vision of creating a more vigorous society by exploring the potential to provide relief
View HTML
Toggle Summary Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting
Expedited SAGE-217 development plan to support potential NDA submission for MDD and PPD Previously completed placebo-controlled study in MDD considered as pivotal; initiation of one additional Phase 3 pivotal trial anticipated in 2H of 2018 Ongoing study in PPD designated as pivotal; results
View HTML